Clinical Trial Update: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cardiovascular risk markers in psoriasis patients treated with secukinumab; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2017-07-13